Are there ketamine clinics in Ocean City?
Our directory currently does not list any clinics offering ketamine or Spravato physically located in Ocean City. Residents of Worcester County typically travel to regional clinical offices in places like Annapolis, Columbia, or Bethesda to undergo these specialized psychiatric treatments. Contact clinics directly for current availability.
Can I drive back to Ocean City after treatment?
No, driving is strictly prohibited after receiving Spravato or IV ketamine. You must have a responsible adult provide transportation back to Ocean City. Furthermore, you cannot drive or operate heavy machinery until the day following your treatment, and only after you have had a restful night of sleep.
Is Spravato FDA-approved for chronic pain?
No. Spravato is an FDA-approved medication specifically indicated for certain types of treatment-resistant depression and depressive symptoms in adults with major depressive disorder who exhibit acute suicidal ideation or behavior. It is not FDA-approved for treating chronic pain, obsessive-compulsive disorder, or post-traumatic stress disorder.
Will my insurance cover IV ketamine therapy?
Because intravenous (IV) ketamine is used off-label for psychiatric conditions, it is typically not covered by standard health insurance plans. Patients from the Eastern Shore usually pay out-of-pocket for these infusions. Always request a written estimate to understand the full financial commitment before beginning any off-label therapy.
Why must I be monitored after Spravato?
Spravato carries risks of significant side effects, including sedation, dissociation, and sudden spikes in blood pressure. To ensure patient safety, the FDA requires that the medication be administered in a certified healthcare setting where medical personnel observe you for at least two hours after your dose.
Are at-home ketamine prescriptions safe?
Spravato is never administered at home. Some providers may prescribe off-label compounded ketamine for home use; however, these formulations lack FDA approval for psychiatric care. The FDA has issued warnings about potential severe safety risks associated with taking compounded ketamine products without direct, on-site clinical monitoring.